[go: up one dir, main page]

ZA200904531B - Phosphoinositide 3-kinase inhibitor compounds and methods of use - Google Patents

Phosphoinositide 3-kinase inhibitor compounds and methods of use

Info

Publication number
ZA200904531B
ZA200904531B ZA200904531A ZA200904531A ZA200904531B ZA 200904531 B ZA200904531 B ZA 200904531B ZA 200904531 A ZA200904531 A ZA 200904531A ZA 200904531 A ZA200904531 A ZA 200904531A ZA 200904531 B ZA200904531 B ZA 200904531B
Authority
ZA
South Africa
Prior art keywords
phosphoinositide
methods
kinase inhibitor
inhibitor compounds
compounds
Prior art date
Application number
ZA200904531A
Other languages
English (en)
Inventor
Georgette Castanedo
Jennafer Dotson
Richard Goldsmith
Janet Gunzner
Tim Heffron
Simon Mathieu
Alan Olivero
Steven Staben
Daniel P Sutherlin
Vickie Tsui
Shumei Wang
Bing-Yan Zhu
Tracy Bayliss
Irina Chuckowree
Adrian FOLKES
Nan Chi Wan
Original Assignee
Hoffmann La Roche
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39403189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200904531(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Genentech Inc filed Critical Hoffmann La Roche
Publication of ZA200904531B publication Critical patent/ZA200904531B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
ZA200904531A 2006-12-07 2007-12-05 Phosphoinositide 3-kinase inhibitor compounds and methods of use ZA200904531B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87342206P 2006-12-07 2006-12-07

Publications (1)

Publication Number Publication Date
ZA200904531B true ZA200904531B (en) 2010-09-29

Family

ID=39403189

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200904531A ZA200904531B (en) 2006-12-07 2007-12-05 Phosphoinositide 3-kinase inhibitor compounds and methods of use

Country Status (19)

Country Link
US (1) US9487533B2 (xx)
EP (1) EP2114950B1 (xx)
JP (1) JP5500990B2 (xx)
KR (1) KR101507182B1 (xx)
CN (1) CN101675053B (xx)
AR (1) AR064154A1 (xx)
AU (1) AU2007333243B2 (xx)
BR (1) BRPI0717907A2 (xx)
CA (1) CA2671845C (xx)
CL (1) CL2007003523A1 (xx)
ES (1) ES2571028T3 (xx)
IL (1) IL199151A (xx)
MX (1) MX2009005925A (xx)
NO (1) NO342697B1 (xx)
PE (1) PE20081353A1 (xx)
RU (1) RU2470936C2 (xx)
TW (1) TW200829594A (xx)
WO (1) WO2008073785A2 (xx)
ZA (1) ZA200904531B (xx)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1679668B1 (en) * 1996-09-04 2010-01-27 Intertrust Technologies Corp. Trusted infrastructure support systems, methods and techniques for secure electronic commerce, electronic transactions, commerce process control and automation, distributed computing, and rights management
EP2114949A1 (en) 2006-12-07 2009-11-11 F.Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
US7893060B2 (en) * 2007-06-12 2011-02-22 F. Hoffmann-La Roche Ag Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase
JP5658565B2 (ja) * 2007-09-12 2015-01-28 ジェネンテック， インコーポレイテッド ホスホイノシチド３−キナーゼ阻害剤化合物と化学療法剤との組合せ、および使用方法
CA2704711C (en) 2007-09-24 2016-07-05 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use
JP5348725B2 (ja) * 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
GB0721095D0 (en) * 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
PE20110403A1 (es) * 2008-07-31 2011-07-04 Genentech Inc Compuestos biciclicos fusionados de pirimidina en el tratamiento del cancer
US20110172217A1 (en) * 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
EP2344446A4 (en) 2008-10-17 2012-04-04 Akaal Pharma Pty Ltd S1P RECEPTOR MODULATORS
CN102186845B (zh) * 2008-10-17 2016-09-07 阿卡制药有限公司 S1p受体调节剂以及它们的用途
DK2385832T3 (en) 2009-01-08 2015-09-21 Curis Inc Phosphoinositid-3-kinase-inhibitorer med en zink-bindingsdel
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
WO2010105008A2 (en) 2009-03-12 2010-09-16 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
ES2665277T3 (es) * 2009-03-13 2018-04-25 Katholieke Universiteit Leuven K.U. Leuven R&D Análogos de purina y su uso como agentes inmunosupresores
US8785651B2 (en) 2009-03-24 2014-07-22 Sumitomo Chemical Company, Limited Method for manufacturing a boronic acid ester compound
AU2010254161A1 (en) * 2009-05-27 2011-11-10 F. Hoffmann-La Roche Ag Bicyclic pyrimidine PI3K inhibitor compounds selective for p110 delta, and methods of use
EP2451811A1 (en) * 2009-05-27 2012-05-16 F. Hoffmann-La Roche AG Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
US20100331305A1 (en) * 2009-06-24 2010-12-30 Genentech, Inc. Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
NZ599090A (en) 2009-09-28 2014-02-28 Hoffmann La Roche Benzoxepin pi3k inhibitor compounds and methods of use
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
EP3444242A3 (en) 2009-11-05 2019-03-20 Rhizen Pharmaceuticals S.A. Novel benzopyran kinase modulators
RU2607635C2 (ru) * 2009-11-12 2017-01-10 Ф.Хоффманн-Ля Рош Аг N-9-замещенные пуриновые соединения, композиции и способы применения
KR101447789B1 (ko) * 2009-11-12 2014-10-06 에프. 호프만-라 로슈 아게 Ｎ-7 치환된 퓨린 및 피라졸로피리미딘 화합물, 조성물 및 사용 방법
CN102762565A (zh) 2010-02-22 2012-10-31 弗·哈夫曼-拉罗切有限公司 吡啶并[3,2-d]嘧啶PI3δ抑制剂化合物及使用方法
JP2013525308A (ja) * 2010-04-16 2013-06-20 キュリス，インコーポレイテッド Ｋ−ｒａｓ変異を有する癌の治療
BR112012033253A2 (pt) * 2010-06-23 2016-11-22 Hanmi Science Co Ltd novos derivados de pirimidina fundidos para inibição da atividade de tirosina quinase
WO2012007493A1 (en) 2010-07-14 2012-01-19 F. Hoffmann-La Roche Ag Purine compounds selective for ρi3κ p110 delta, and methods of use
DE102010049595A1 (de) * 2010-10-26 2012-04-26 Merck Patent Gmbh Chinazolinderivate
KR20140099556A (ko) 2010-12-16 2014-08-12 에프. 호프만-라 로슈 아게 트라이사이클릭 pi3k 억제제 화합물 및 이의 사용 방법
EP2667874A4 (en) * 2011-01-27 2014-07-30 Univ Princeton MTOR KINASE HEMMER AS ANTIVIRUS AGENT
CN103476767B (zh) 2011-02-09 2015-06-10 弗·哈夫曼-拉罗切有限公司 作为pi3激酶抑制剂的杂环化合物
JP2014511395A (ja) * 2011-03-09 2014-05-15 セルジーン アヴィロミクス リサーチ， インコーポレイテッド Ｐｉ３キナーゼインヒビターおよびその使用
CA2825966A1 (en) 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Benzoxazepin compounds selective for pi3k p110 delta and methods of use
ME02451B (me) 2011-04-01 2016-09-20 Curis Inc Inhibitor fosfoinozitid 3-kinaze sa delom koji vezuje cink
PH12013502033A1 (en) 2011-04-08 2014-01-06 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
PT2705029T (pt) 2011-05-04 2019-02-01 Rhizen Pharmaceuticals S A Novos compostos como moduladores de proteína quinases
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
EP2776439B1 (en) 2011-11-09 2018-07-04 Janssen Sciences Ireland UC Purine derivatives for the treatment of viral infections
WO2013078126A1 (en) 2011-11-23 2013-05-30 Cancer Research Technology Limited Thienopyrimidine inhibitors of atypical protein kinase c
WO2013152717A1 (zh) 2012-04-10 2013-10-17 上海昀怡健康管理咨询有限公司 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用
JP6301316B2 (ja) 2012-05-23 2018-03-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 内胚葉細胞および肝実質細胞の組成物ならびにそれらの細胞を入手および使用する方法
NZ702244A (en) 2012-06-08 2017-06-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
HRP20171610T1 (hr) 2012-07-04 2018-03-23 Rhizen Pharmaceuticals S.A. Selektivni inhibitori pi3k delta
WO2014009509A1 (en) 2012-07-13 2014-01-16 Janssen R&D Ireland Macrocyclic purines for the treatment of viral infections
US9499549B2 (en) 2012-10-10 2016-11-22 Janssen Sciences Ireland Uc Pyrrolo[3,2-]pyrimidine derivatives for the treatment of viral infections and other diseases
JP6123097B2 (ja) * 2012-10-10 2017-05-10 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト チエノピリミジン化合物を製造するための方法
WO2014068070A1 (en) 2012-10-31 2014-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
UA118341C2 (uk) 2012-11-16 2019-01-10 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Гетероциклічні заміщені похідні 2-амінохіназоліну для лікування вірусних інфекцій
UA118751C2 (uk) 2013-02-21 2019-03-11 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Похідні 2-амінопіримідину для лікування вірусних інфекцій
BR112015024411B1 (pt) 2013-03-29 2022-02-22 Janssen Sciences Ireland Uc Desaza-purinonas macrocíclicas para o tratamento de infeções virais e composição farmacêutica que os compreende
DE102013008118A1 (de) * 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
AU2014270418B2 (en) 2013-05-24 2017-11-30 Janssen Sciences Ireland Uc Pyridone derivatives for the treatment of viral infections and further diseases
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
NO3030563T3 (xx) 2013-06-27 2018-01-06
CA2913691C (en) 2013-07-30 2022-01-25 Janssen Sciences Ireland Uc Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
CN104513254B (zh) 2013-09-30 2019-07-26 上海璎黎药业有限公司 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3159339B1 (en) * 2014-06-09 2020-11-25 Sumitomo Chemical Company, Limited Method for producing pyridine compound
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
KR20160082062A (ko) 2014-12-30 2016-07-08 한미약품 주식회사 싸이옥소 퓨로피리미디논 유도체의 제조방법 및 이에 사용되는 중간체
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
EP3314265B1 (en) 2015-06-29 2019-07-24 H. Hoffnabb-La Roche Ag Methods of treatment with taselisib
CN106467545B (zh) * 2015-08-20 2018-10-16 北大方正集团有限公司 一种噻吩并嘧啶化合物
CN109311868B (zh) 2015-12-22 2022-04-01 尚医治疗有限责任公司 用于治疗癌症和炎性疾病的化合物
WO2018001952A1 (en) * 2016-06-29 2018-01-04 F. Hoffmann-La Roche Ag Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hbv infection
CN109476675B (zh) 2016-07-01 2022-12-09 爱尔兰詹森科学公司 用于治疗病毒性感染的二氢吡喃并嘧啶衍生物
AU2017335205B2 (en) 2016-09-29 2021-11-04 Janssen Sciences Ireland Unlimited Company Pyrimidine prodrugs for the treatment of viral infections and further diseases
CN110573518A (zh) 2017-01-26 2019-12-13 尤拉·S·赞特里佐斯 被取代的双环嘧啶基化合物及其组合物和用途
CN107163061A (zh) * 2017-04-14 2017-09-15 江西科技师范大学 含吡唑啉结构的噻吩并嘧啶类化合物的制备及应用
IL271230B2 (en) 2017-06-21 2024-06-01 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
WO2020055840A1 (en) 2018-09-11 2020-03-19 Curis Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN109540859B (zh) * 2018-11-27 2021-02-09 上海交通大学 一种水体中抗生素的分析和含量预测方法
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
EP3911649A1 (en) 2019-01-17 2021-11-24 F. Hoffmann-La Roche AG A process for the preparation of tetrahydropyridopyrimidines
CN113087718B (zh) * 2020-01-09 2024-02-09 四川科伦博泰生物医药股份有限公司 噻吩并嘧啶酮类化合物及其医药应用
EP4161519A4 (en) * 2020-06-03 2024-07-17 Yumanity Therapeutics, Inc. PURINES AND METHODS OF USE
WO2022152229A1 (zh) * 2021-01-15 2022-07-21 深圳微芯生物科技股份有限公司 一类吗啉衍生物及其制备方法和应用
CN115991716B (zh) * 2021-10-19 2025-10-17 中国药科大学 嘧啶并环类化合物及其衍生物、制备方法、药物组合物和应用
CN116262758B (zh) * 2021-12-15 2025-02-28 上海博悦生物科技有限公司 7-甲基噻唑并[5,4-d]嘧啶类化合物、制备方法及其用途
CN114539293B (zh) * 2022-02-24 2023-09-22 广东晨康生物科技有限公司 一种噻吩并嘧啶类化合物或其药学上可接受的盐及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
BE759493A (fr) 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
DE2050814A1 (de) 1970-10-16 1972-04-20 Dr. Karl Thomae Gmbh, 7950 Biberach Neue Verfahren zur Herstellung von 2-(5-Nitro-2-furyl)-thieno eckige Klammer auf 3,2-d eckige Klammer zu pyrimidinen
DE1959403A1 (de) 1969-11-26 1971-06-03 Thomae Gmbh Dr K Neue 2-(5-Nitro-2-furyl)-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
US3763156A (en) 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
DE2058085A1 (de) * 1970-11-26 1972-05-31 Thomae Gmbh Dr K Neues Verfahren zur Herstellung von 4-Morpholino-thieno[3,2-d]pyrimidinen
RO62428A (fr) 1971-05-04 1978-01-15 Thomae Gmbh Dr K Procede pour la preparation des thyeno-(3,2-d)-pyrimidines
CH592668A5 (xx) * 1973-10-02 1977-10-31 Delalande Sa
GB1570494A (en) 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
US4196207A (en) 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
RU1391052C (ru) * 1986-08-25 1993-11-30 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные 5-формилтиено [2,3-D]пиримидина, обладающие противогерпетической активностью
US5075305A (en) 1991-03-18 1991-12-24 Warner-Lambert Company Compound, composition and use
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
JP3649395B2 (ja) 2000-04-27 2005-05-18 山之内製薬株式会社 縮合ヘテロアリール誘導体
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
CN1458933A (zh) * 2000-09-29 2003-11-26 日本曹达株式会社 噻吩并嘧啶化合物及其盐以及其制备方法
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
WO2006004601A1 (en) * 2004-06-03 2006-01-12 Nordson Corporation Color change for powder coating material application system
EP1806347A4 (en) 2004-10-08 2009-07-01 Astellas Pharma Inc PYRIMIDINE DERIVATIVES FUSED WITH AN AROMATIC RING
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
BRPI0710866A2 (pt) 2006-04-26 2012-08-14 Hoffmann La Roche compostos farmacÊuticos
TW200801012A (en) 2006-04-26 2008-01-01 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
US8802670B2 (en) 2006-04-26 2014-08-12 F. Hoffmann-La Roche Ag Pharmaceutical compounds
PT2024372E (pt) 2006-04-26 2010-09-16 Hoffmann La Roche Derivado de tieno[3,2-d]pirimidina útil como inibidor de pi3k
GB0608820D0 (en) 2006-05-04 2006-06-14 Piramed Ltd Pharmaceutical compounds
EP2114949A1 (en) 2006-12-07 2009-11-11 F.Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use

Also Published As

Publication number Publication date
ES2571028T3 (es) 2016-05-23
RU2009125916A (ru) 2011-01-20
BRPI0717907A2 (pt) 2013-11-05
JP2010512337A (ja) 2010-04-22
AU2007333243B2 (en) 2013-03-14
US9487533B2 (en) 2016-11-08
CA2671845A1 (en) 2008-06-19
CL2007003523A1 (es) 2008-08-22
NO20092565L (no) 2009-09-07
IL199151A (en) 2017-01-31
MX2009005925A (es) 2009-08-12
CA2671845C (en) 2015-03-24
TW200829594A (en) 2008-07-16
WO2008073785A3 (en) 2008-08-28
IL199151A0 (en) 2010-03-28
PE20081353A1 (es) 2008-11-12
CN101675053A (zh) 2010-03-17
WO2008073785A2 (en) 2008-06-19
US20080269210A1 (en) 2008-10-30
NO342697B1 (no) 2018-07-09
RU2470936C2 (ru) 2012-12-27
CN101675053B (zh) 2014-03-12
JP5500990B2 (ja) 2014-05-21
KR20090106508A (ko) 2009-10-09
EP2114950A2 (en) 2009-11-11
EP2114950B1 (en) 2016-03-09
KR101507182B1 (ko) 2015-03-30
AR064154A1 (es) 2009-03-18
AU2007333243A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
ZA200904531B (en) Phosphoinositide 3-kinase inhibitor compounds and methods of use
IL204333A (en) Combinations of compounds inhibiting phosphoinositide 3-kinase and chemotherapeutic agents
IL194761A0 (en) Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
IL196956A0 (en) Aza-benzofuranyl compounds and methods of use
IL205747A0 (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
IL197060A0 (en) Aza-benzothiophenyl compounds and methods of use
EP2023718A4 (en) CREATINLIGATE COMPOUNDS AND APPLICATION METHOD THEREFOR
IL239312A0 (en) Use of a TNF inhibitor to treat rodent polyarthritis
PL2439205T3 (pl) Związki karboksamidowe i ich zastosowanie jako inhibitorów kalpainy
ZA200706345B (en) Amino-pyridines as inhibitors of ß-secretase
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
ZA200802485B (en) Phosphatidylinositol 3-kinase inhibitors and methods of their use
EP2026843A4 (en) THERAPEUTIC USES OF RTP801L INHIBITORS
PT2397142T (pt) Utilizações de inibidores da dpp iv
ZA200802822B (en) Raf inhibitor compounds and methods of use thereof
ZA200710969B (en) Raf inhibitor compounds and methods of use thereof
ZA201002317B (en) Parp inhibitor compounds,compositions and methods of use
IL207843A0 (en) Raf inhibitor compounds and methods of use thereof
IL194028A0 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
IL193693A0 (en) Purine compounds and methods of use thereof
ZA200904534B (en) Phosphoinositide 3-kinase inhibitor compounds and methods of use
ZA200900896B (en) Aza-benzofuranyl compounds and methods of use
ZA200901009B (en) Aza-benzothiophenyl compounds and methods of use
GB0504209D0 (en) New use of PDE7 inhibitors